Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 6/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.38 |
| ▸ | KRAS | P01116 | 3/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | LYN | P07948 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31335585 | 0.91 | SPR (0.36) | TRAP1HSP90B1SPRLYNBTK | |
| SCHEMBL31335760 | 0.91 | TRAP1 (0.33) | TRAP1HSP90B1SPRLYNBTK | |
| SCHEMBL31335633 | 0.89 | ABCG2 (0.33) | FGFR1FGFR2FGFR4FGFR3LYN | |
| SCHEMBL31335820 | 0.88 | HSP90B1 (0.35) | TRAP1HSP90B1KRASFGFR1FGFR2 | |
| SCHEMBL31335751 | 0.88 | TRAP1 (0.40) | TRAP1HSP90B1KRASFGFR1FGFR4 | |
| SCHEMBL31335822 | 0.86 | TRAP1 (0.36) | TRAP1HSP90B1SPRLYNBTK | |
| SCHEMBL25267660 | 0.86 | TRAP1 (0.36) | TRAP1HSP90B1KRASSPRLYN | |
| SCHEMBL30378186 | 0.86 | TRAP1 (0.36) | TRAP1HSP90B1KRASSPRLYN | |
| SCHEMBL31335713 | 0.86 | TRAP1 (0.37) | TRAP1HSP90B1SPRLYNBTK | |
| SCHEMBL31335505 | 0.85 | TRAP1 (0.44) | TRAP1HSP90B1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| WO-2024246496-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2024-12-05 | — | — | WO | claimed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246496-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2024-12-05 | — | — | WO | disclosed |